title: [Intrapleural administration of pirarubicin in the treatment of malignant pleural effusion].
abstract: Pirarubicin, a new antineoplastic antibiotic of anthracycline derivative, was injected into the pleural cavity in 15 patients with malignant pleural effusion. The dose of pirarubicin was 40 mg or 80 mg/body. All 15 patients were evaluable for both efficacy and toxicity. Since one evaluable patient received two courses of intrapleural administration of pirarubicin, we evaluated a total of 16 courses. Overall response rate was 81.3% with 7 CR cases, 6 PR cases and 3 NR cases. As toxicities, transient elevation of fever was observed in 81.3%, chest pain in 37.5%, appetite loss in 18.8%, nausea in 12.5% and bone marrow suppression in 6.3% of 16 courses, but no alopecia was observed. Between 40 mg group (n = 8) and 80 mg group (n = 8), no significant difference was observed in response rate, response duration, survival duration or toxicities except for fever. Fever over 38 degrees C was observed in all (100%) the 80 mg group, which was significantly higher than 50% in the 40 mg group. Response duration in cases with fever over 38 degrees C (n = 12) was significantly longer than in cases with maximum fever under 38 degrees C (n = 4). Intrapleural administration of pirarubicin was considered to be effective for the treatment of malignant pleural effusion without severe toxicities.
authors.affiliation: Second Dept. of Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Gotoh
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: N
authors.initials: N
authors.lastname: Hiramori
authors.forename: T
authors.initials: T
authors.lastname: Fujii
authors.forename: Y
authors.initials: Y
authors.lastname: Fujita
authors.forename: T
authors.initials: T
authors.lastname: Kida
authors.forename: T
authors.initials: T
authors.lastname: Arimoto
authors.forename: M
authors.initials: M
authors.lastname: Sakai
authors.forename: Y
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000230:Adenocarcinoma / Q000150:complications; D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D018288:Carcinoma, Small Cell / Q000150:complications; D002637:Chest Pain / Q000139:chemically induced; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000150:complications; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D013274:Stomach Neoplasms / Q000150:complications; D015996:Survival Rate
chemical_list: D004317:Doxorubicin; C027260:pirarubicin